April 15, 2014 — Mevion Medical Systems announced an agreement with Chiyoda Technol Corp. for the exclusive distribution of the Mevion S250 proton therapy system in the Japanese market. Chiyoda Technol is one of Japan’s leading providers of radiation supply, service and monitoring.
The Mevion S250 system is a single-room, gantry-mounted proton accelerator that frees hospitals and private treatment facilities from the high costs, prohibitive space requirements and cumbersome workflow that commonly define the treatment modality.
“The significantly reduced size and cost of the Mevion S250, paired with cutting-edge technology, is a perfect fit for the very progressive Japanese radiation therapy market,” said Kazuhiko Yamaguchi, president of Chiyoda Technol Corp. “We have a strong tradition of introducing state-of-the-art medical products and with the addition of the Mevion S250 proton therapy system, we are fulfilling the demand of our foremost customers and we expect to significantly increase the number of proton therapy centers in the next five years.”
“Mevion is proud to expand its partnership with Chiyoda Technol to provide this revolutionary proton therapy platform to clinicians and patients in Japan”, said Joseph K. Jachinowski, CEO of Mevion. “With Japan’s 20-year leadership in the clinical use of proton therapy, the Japanese market has always been a high priority and we are excited to see the very positive response the Mevion S250 is receiving from all proton experts.”
The Mevion S250 is installed at the Kling Proton Therapy Center at Barnes-Jewish Hospital at Washington University in St. Louis, benefiting pediatric patients and other cancer patients where proton therapy treatment is indicated. Five additional systems are under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J.; Stephenson Cancer Center at the University of Oklahoma in Oklahoma City; First Coast Oncology in Jacksonville, Fla.; University of Florida Health Cancer Center at Orlando Health; and University Hospitals Seidman Cancer Center in Cleveland.
For more information: www.mevion.com
April 25, 2024 
